CN114181967A - 一种能同时表达cd19 car和敲除t细胞表面pd-1表达的质粒结构及构建方法 - Google Patents
一种能同时表达cd19 car和敲除t细胞表面pd-1表达的质粒结构及构建方法 Download PDFInfo
- Publication number
- CN114181967A CN114181967A CN202111383546.6A CN202111383546A CN114181967A CN 114181967 A CN114181967 A CN 114181967A CN 202111383546 A CN202111383546 A CN 202111383546A CN 114181967 A CN114181967 A CN 114181967A
- Authority
- CN
- China
- Prior art keywords
- cells
- plasmid
- expression
- plasmid structure
- knocking out
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710089372 Programmed cell death protein 1 Proteins 0.000 title claims abstract description 37
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 35
- 239000013612 plasmid Substances 0.000 title claims abstract description 33
- 102100023990 60S ribosomal protein L17 Human genes 0.000 title claims 11
- 238000010276 construction Methods 0.000 title abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 26
- 241000713666 Lentivirus Species 0.000 claims description 15
- 239000002609 medium Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 9
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- 210000005087 mononuclear cell Anatomy 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 208000021601 lentivirus infection Diseases 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract description 15
- 108091033409 CRISPR Proteins 0.000 abstract description 8
- 210000000987 immune system Anatomy 0.000 abstract description 6
- 241000700605 Viruses Species 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000001890 transfection Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241000973497 Siphonognathus argyrophanes Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种能同时表达CD19CAR和敲除T细胞表面PD‑1表达的质粒结构及构建方法,在PD‑1的基因序列中选取23个碱基序列作为靶点,构建pGL3‑gRNA‑cas9‑U6‑PD‑1质粒,所述碱基序列为SEQ ID:agccg aagac cttag agcag tag。本发明利用Crispr/Cas9系统,敲除T细胞中的PD‑1基因,使其不表达PD‑1蛋白,打开免疫系统的刹车闸,增强免疫系统的功能。
Description
技术领域
本发明属于生物细胞技术领域,特别是涉及一种能同时表达CD19 CAR 和敲除T细胞表面PD-1表达的质粒结构。
背景技术
CAR-T(Chimeric Antigen Receptor T-Cell Immunotherapy,嵌合抗原受体 T细胞免疫疗法)是近年来发展起来的新的过继免疫细胞治疗手段,通过基因工程手段修饰T细胞,使其表达嵌合抗原受体,嵌合抗原受体可以特异性识别肿瘤相关抗原靶点,识别结合后将激活增殖T细胞的信号传递至胞内,引起T细胞激活和增殖,从而有效杀伤肿瘤细胞。
与普通的免疫细胞治疗相比,CAR-T技术具有许多独特的优势,如CAR 能非MHC依赖性识别肿瘤抗原,不需要经过APC。肿瘤表面蛋白类和脂类抗原都可以作为靶点;有共刺激分子,能有效增强T细胞增殖。因此该技术被认为是有望彻底攻克人类癌症的独特方法。
目前,CAR-T免疫治疗已在许多临床实验上取得巨大进展。其中,针对 B相关抗原CD19阳性的B细胞恶性肿瘤,如急性B-淋巴细胞白血病,慢性 B-淋巴细胞白血病,B细胞霍奇金氏淋巴瘤和非霍奇金氏淋巴瘤, CAR-T-CD19T细胞免疫治疗疗效显著,已有报告显示CAR-T-CD19治疗在成人和儿童复发和难治性B-ALL中可以获得高达90%的完全缓解率。研究报告也显示,几种用不同结构设计的CAR-CD19的临床试验治疗都显示了相似的良好疗效。有些患者经CAR-T治疗后还获得了持久性缓解,不需要额外的其他治疗。
发明内容
本发明主要解决的技术问题是提供一种能同时表达CD19 CAR和敲除T 细胞表面PD-1表达的质粒结构及构建方法,利用Crispr/Cas9系统,敲除T 细胞中的PD-1基因,使其不表达PD-1蛋白,打开免疫系统的刹车闸,增强免疫系统的功能。
为解决上述技术问题,本发明采用的一个技术方案是:一种能同时表达 CD19 CAR和敲除T细胞表面PD-1表达的质粒结构,在PD-1的基因序列中选取23个碱基序列作为靶点,构建pGL3-gRNA-cas9-U6-PD-1质粒。
进一步地说,所述碱基序列为SEQ ID:agccg aagac cttag agcag tag。
一种能同时表达CD19 CAR和敲除T细胞表面PD-1表达的质粒结构的构建方法,包括以下步骤:
S1、取患者自身的外周血,分离单个核细胞,用培养基诱导培养16-18 小时后,加入重组白细胞介素-2和RPMI1640诱导继续培养1-2天;每隔三天倍比加含有重组白细胞介素-2的培养基,培养至第14天,收获患者自体单核细胞诱导的T细胞,用于慢病毒感染;
S2、利用慢病毒包装体系将PD-1基因包装到慢病毒中,将携带PD-1基因的慢病毒感染单核细胞诱导的T细胞,即可。
进一步地说,所述步骤S2的具体操作为:所述pGL3-gRNA-cas9-U6-PD-1 质粒和慢病毒共同转染细胞,所述转染细胞内PD-1基因被包装成慢病毒颗粒,释放到细胞外,收集含有慢病毒的上清,并用收集到的上清感染诱导的T细胞。
进一步地说,所述步骤S1中,培养基含有氨苄霉素。
进一步地说,所述步骤S1中,用流式细胞术检测CIK细胞的分子标记 CD3+、CD56+的阳性表达率。
进一步地说,所述步骤S1中,当CD3+阳性率>80%,CD3+CD56+双阳性率>20%,视为CIK诱导成功。
进一步地说,所述步骤S1中,每隔三天需在培养基中同时加入3%的患者自体血浆。
进一步地说,所述步骤S2中,所述转染细胞为PBMC细胞。
本发明的有益效果:本发明利用Crispr/Cas9系统来敲除PD-1基因,还利用Crispr/Cas9技术修饰的T细胞,所述T细胞表面含有PD-1蛋白,可与癌细胞表面的PD-L1蛋白结合,阻碍活化T细胞攻击癌细胞;敲除T细胞中的 PD-1基因,打开了免疫系统的刹车闸,增强免疫系统的功能。
具体实施方式
下面对本发明的较佳实施例进行详细阐述,以使本发明的优点和特征能更易于被本领域技术人员理解,从而对本发明的保护范围做出更为清楚明确的界定。
实施例1:将基因片段PD-1插入慢病毒表达载体pGL3-gRNA-cas9-U6
上述PD-1的核酸人工序列(碱基序列为SEQ ID:agccg aagac cttag agcag tag),委托汉恒生物科技有限公司合成,插入pGL3-gRNA-cas9-U6载体,转化到E.coli,经测序正确后,使用OMEGA公司的质粒纯化试剂盒提取并纯化质粒,获得重组表达载体的高品质质粒。
实施例2:pGL3-gRNA-cas9-U6敲除PD-1的T细胞的制备
(一)异质性T细胞——CIK的制备
取75ml患者外周血,用TBD样本密度分离液,分离出单核细胞。用含有800IU/mL的氨苄霉素的培养基诱导培养16-18小时后,加入1200IU/mL的重组白细胞介素2和50ng/mL的RPMI1640继续培养1-2天。每隔三天倍比加液,同时加入3%的自体血浆,培养至第14天,流式细胞术检测CIK细胞中的CD3和CD56的阳性表达率,当CD3+阳性率﹥80%,CD3+CD56+双阳性率﹥20%,视为CIK诱导成功,并留取该CIK待病毒感染。
(二)慢病毒包装质粒脂质体转染PBMC细胞
从液氮罐中取出冻存的PBMC细胞,迅速丢入37℃水浴锅中并快速晃动,尽量在1~2min内使细胞溶液完全溶解。将细胞溶液转移到15mL离心管中,并在其中加上1mL新鲜的完全培养基,混匀后离心,156g,5min。去掉上清,加入1mL新鲜的完全培养基重悬细胞沉淀后,转入100mm培养皿,每个培养皿补足到10mL培养基。将培养皿平稳放入培养箱中培养。第二天观察细胞存活率,并更换培养基。以后每天观察细胞生长情况。
将状态良好的PBMC细胞铺在100mm的培养皿中,置于培养箱中培养2 天。观察细胞密度,达到70~80%的汇合率即可进行转染。转染后更换含10%胎牛血清FBS的新鲜完全培养基,转染后6h进行换液。
转染后48h和72h分别两次收集病毒上清。在48h收毒时,将100mm dish 中的培养基倒入50mL离心管中,注意培养皿壁不要接触离心管口,以防出现细菌污染,随后补入10mL含10%FBS的新鲜完全培养基,平稳置于恒温培养箱中继续培养。在72h收毒时,直接将100mm dish中的培养基倒入50mL 离心管中,同样注意培养皿壁不要接触离心管口,以防出现细菌污染。收完 72h的病毒原液后,该dish便可以舍弃。将50mL离心管中的病毒上清,4℃, 2000g,10min,去除细胞碎片;然后收集病毒原液上清置于超速离心机中,4℃,82700g,离心120min,最后将慢病毒超离液分装到灭菌处理的病毒管中。按照要求分装病毒,-80℃冰箱保存。
(三)慢病毒感染CIK细胞及感染后CIK细胞的扩增培养
从-80℃拿出2ml病毒液解冻后加入培养基,将聚凝胺加入上述培养基稀释,使其终浓度为10μg/ml。用该病毒液重悬1×106个上述诱导的CIK细胞。将细胞悬液加入到6孔板中,使病毒颗粒数与CIK细胞数比例约为2:1,400g, 120min。37℃,5%的CO2培养箱中培养16小时后,用新鲜培养基稀释一倍,继续培养1天后收集细胞去除剩余的病毒颗粒进行正常培养。为了提高CIK 细胞的感染效率,可重复此感染步骤1-2次。根据细胞生长状态及时加入新鲜的完全培养基,培养15-17天使细胞扩增至足够的用量。
(四)利用流式细胞技术检测pGL3-gRNA-cas9-U6在CIK中的表达效率;
将105个扩增得到的细胞重悬于100μl FACS缓冲液(含2mmol/l EDTA 和0.5%BSA的PBS)中,与Goat anti-Human IgG Antibody,FITC conjugate室温孵育30分钟,生理盐水清洗两次后,通过流式细胞仪检测FITC荧光信号,测量FITC阳性细胞比率,反映CAR-T细胞在总细胞中的比率。
以上所述仅为本发明的实施例,并非因此限制本发明的专利范围,凡是利用本发明说明书内容所作的等效结构变换,或直接或间接运用在其他相关的技术领域,均同理包括在本发明的专利保护范围内。
序列表
<110> 东莞市麦亘生物科技有限公司
<120> 一种能同时表达CD19 CAR和敲低T细胞表面PD-1表达的质粒结构及构建方法
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA
<213> 人工序列
<400> 1
agccgaagac cttagagcag tag 23
Claims (9)
1.一种能同时表达CD19 CAR和敲除T细胞表面PD-1表达的质粒结构,其特征在于:在PD-1的基因序列中选取23个碱基序列作为靶点,构建pGL3-gRNA-cas9-U6-PD-1质粒。
2.根据权利要求1所述的一种能同时表达CD19 CAR和敲除T细胞表面PD-1表达的质粒结构,其特征在于:所述碱基序列为SEQ ID:agccg aagac cttag agcag tag。
3.根据权利要求1所述的一种能同时表达CD19 CAR和敲除T细胞表面PD-1表达的质粒结构的构建方法,其特征在于:包括以下步骤:
S1、取患者自身的外周血,分离单个核细胞,用培养基诱导培养16-18小时后,加入重组白细胞介素-2和RPMI1640诱导继续培养1-2天;每隔三天倍比加含有重组白细胞介素-2的培养基,培养至第14天,收获患者自体单核细胞诱导的T细胞,用于慢病毒感染;
S2、利用慢病毒包装体系将PD-1基因包装到慢病毒中,将携带PD-1基因的慢病毒感染单核细胞诱导的T细胞,即可。
4.根据权利要求1所述的一种能同时表达CD19 CAR和敲除T细胞表面PD-1表达的质粒结构的构建方法,其特征在于:所述步骤S2的具体操作为:所述pGL3-gRNA-cas9-U6-PD-1质粒和慢病毒共同转染细胞,所述转染细胞内PD-1基因被包装成慢病毒颗粒,释放到细胞外,收集含有慢病毒的上清,并用收集到的上清感染诱导的T细胞。
5.根据权利要求1所述的一种能同时表达CD19 CAR和敲除T细胞表面PD-1表达的质粒结构的构建方法,其特征在于:所述步骤S1中,培养基含有氨苄霉素。
6.根据权利要求1所述的一种能同时表达CD19 CAR和敲除T细胞表面PD-1表达的质粒结构的构建方法,其特征在于:所述步骤S1中,用流式细胞术检测CIK细胞的分子标记CD3+、CD56+的阳性表达率。
7.根据权利要求1所述的一种能同时表达CD19 CAR和敲除T细胞表面PD-1表达的质粒结构的构建方法,其特征在于:所述步骤S1中,当CD3+阳性率>80%,CD3+CD56+双阳性率>20%,视为CIK诱导成功。
8.根据权利要求1所述的一种能同时表达CD19 CAR和敲除T细胞表面PD-1表达的质粒结构的构建方法,其特征在于:所述步骤S1中,每隔三天需在培养基中同时加入3%的患者自体血浆。
9.根据权利要求4所述的一种能同时表达CD19 CAR和敲除T细胞表面PD-1表达的质粒结构的构建方法,其特征在于:所述步骤S2中,所述转染细胞为PBMC细胞。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111383546.6A CN114181967A (zh) | 2021-11-22 | 2021-11-22 | 一种能同时表达cd19 car和敲除t细胞表面pd-1表达的质粒结构及构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111383546.6A CN114181967A (zh) | 2021-11-22 | 2021-11-22 | 一种能同时表达cd19 car和敲除t细胞表面pd-1表达的质粒结构及构建方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114181967A true CN114181967A (zh) | 2022-03-15 |
Family
ID=80541129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111383546.6A Pending CN114181967A (zh) | 2021-11-22 | 2021-11-22 | 一种能同时表达cd19 car和敲除t细胞表面pd-1表达的质粒结构及构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114181967A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107119021A (zh) * | 2017-07-04 | 2017-09-01 | 王小平 | Pd‑1敲除cd19car‑t细胞的制备 |
CN107699591A (zh) * | 2017-05-09 | 2018-02-16 | 山东兴瑞生物科技有限公司 | 一种敲除pd‑1的t细胞制备方法及其应用 |
CN108531457A (zh) * | 2018-04-10 | 2018-09-14 | 杭州荣泽生物科技有限公司 | 一种Cas9/RNP敲除T细胞PD-1和LAG3基因及制备CAR-T细胞的方法 |
CN112239759A (zh) * | 2020-10-28 | 2021-01-19 | 重庆斯德姆生物技术有限公司 | 用于敲低PD1基因表达的microRNA及其嵌合抗原受体-T/NK细胞的构建 |
-
2021
- 2021-11-22 CN CN202111383546.6A patent/CN114181967A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107699591A (zh) * | 2017-05-09 | 2018-02-16 | 山东兴瑞生物科技有限公司 | 一种敲除pd‑1的t细胞制备方法及其应用 |
CN107119021A (zh) * | 2017-07-04 | 2017-09-01 | 王小平 | Pd‑1敲除cd19car‑t细胞的制备 |
CN108531457A (zh) * | 2018-04-10 | 2018-09-14 | 杭州荣泽生物科技有限公司 | 一种Cas9/RNP敲除T细胞PD-1和LAG3基因及制备CAR-T细胞的方法 |
CN112239759A (zh) * | 2020-10-28 | 2021-01-19 | 重庆斯德姆生物技术有限公司 | 用于敲低PD1基因表达的microRNA及其嵌合抗原受体-T/NK细胞的构建 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210154231A1 (en) | Method for producing t cells modified by chimeric antigen receptor | |
JP5805089B2 (ja) | 細胞集団の製造方法 | |
US11932872B2 (en) | Dual chimeric antigen receptor-t cell which can be regulated, construction method therefor and use thereof | |
WO2018058431A1 (zh) | 一种嵌合抗原受体分子及其应用 | |
CN108546679B (zh) | 在体外大量扩增人类成熟高活性树突状细胞的方法及其应用 | |
CN110317822B (zh) | Trop2嵌合抗原受体、其t细胞及其制备方法和用途 | |
CN110055269B (zh) | 人间皮素嵌合抗原受体、其t细胞及其制备方法和用途 | |
CN110684730A (zh) | 一种利用滋养细胞高效扩增nk细胞的制备方法 | |
WO2009139413A1 (ja) | サイトカイン誘導キラー細胞含有細胞集団の製造方法 | |
CN106834354A (zh) | 一种修饰的增强型靶向免疫细胞群的制备方法和用途 | |
CN106978442B (zh) | 一种嵌合抗原受体t细胞的制备方法 | |
CN111139222B (zh) | 一种重组间充质干细胞及其制备方法和用途 | |
CN105384826A (zh) | 表达嵌合抗原受体的脐血有核细胞及其应用 | |
CN114540294A (zh) | 靶向肿瘤部位递送基因药物的干细胞外泌体的制备与应用 | |
CN108949759B (zh) | 敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用 | |
CN111349601A (zh) | 一种高效体外扩增培养具有强杀伤力的自然杀伤性细胞的方法 | |
CN116478931A (zh) | 一种高亲和型抗肿瘤nk细胞及其制备方法和应用 | |
CN114181967A (zh) | 一种能同时表达cd19 car和敲除t细胞表面pd-1表达的质粒结构及构建方法 | |
CN113462649B (zh) | Mek抑制剂在减少car-t细胞耗竭和终末分化中的应用 | |
CN112725283B (zh) | 靶向cd30和cd24的双靶点car-t细胞的构建方法及应用 | |
CN113832190A (zh) | 一种利用基因工程修饰的滋养细胞的制备方法及其应用 | |
CN111378690B (zh) | 一种嵌合抗原受体t细胞的制备方法 | |
CN112023048A (zh) | 一种对阿糖胞苷耐药的稳转重组b淋巴细胞白血病细胞系的构建方法及其应用 | |
CN106267417B (zh) | Aids治疗反应器 | |
CN106267409B (zh) | 艾滋病生物治疗反应器 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220315 |
|
RJ01 | Rejection of invention patent application after publication |